BIOINVEST BREAKING NEWS – The Medicines Company (MDCO) – Inclisiran FDA Path Clear After End of Phase II Meeting – Lower Risk, Value Enhanced – The Medicines Company announced that the primary endpoint of the Phase III registrational trial will be LDL-C levels. This is a major positive for MDCO – significantly reduces the risk and increases the value of Inclisiran.
To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.